NPPA and nervous system disorder: In addition, the specific anti-inflammatory properties we observed support the potential for use of MSC, particularly HUCPVC, as a therapeutic option for targeting inflammation-driven activated KP metabolites and glutamatergic systems linked to neurological diseases and affective disorders.